A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
Summary
- Eligibility
- for people ages 12-99 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Adil Daud
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Adil Daud
Professor, Medicine, School of Medicine. Authored (or co-authored) 208 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Erasca, Inc.
- ID
- NCT05907304
- Phase
- Phase 1 Solid Tumor Research Study
- Study Type
- Interventional
- Participants
- Expecting 115 study participants
- Last Updated